33.04
-0.12(-0.36%)
Currency In USD
| Previous Close | 33.16 |
| Open | 33.45 |
| Day High | 33.53 |
| Day Low | 32.72 |
| 52-Week High | 61.38 |
| 52-Week Low | 29.31 |
| Volume | 1.34M |
| Average Volume | 2.04M |
| Market Cap | 3.95B |
| PE | -6.25 |
| EPS | -5.29 |
| Moving Average 50 Days | 33.98 |
| Moving Average 200 Days | 44.97 |
| Change | -0.12 |
If you invested $1000 in Cytokinetics, Incorporated (CYTK) 10 years ago, it would be worth $5,067.48 as of July 01, 2025 at a share price of $33.04. Whereas If you bought $1000 worth of Cytokinetics, Incorporated (CYTK) shares 5 years ago, it would be worth $1,399.41 as of July 01, 2025 at a share price of $33.04.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program
GlobeNewswire Inc.
Jun 10, 2025 11:30 AM GMT
Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 4th, 2025 SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today ann
Cytokinetics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 29, 2025 8:00 PM GMT
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to participate in a fireside chat at the Jefferies Global Healthcare
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress
GlobeNewswire Inc.
May 18, 2025 12:00 PM GMT
Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patientswith Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions HEOR Analyses of Real-World Data Reveal Disparities in Outcomes In Females and Older Patients with Non-